Greater cooperation needed on value added medicines to improve patient-centric innovation, says trade group

The 1st Value Added Medicines conference organized by the Value Added Medicines Group, a sector group of the generics and biosimilars trade group Medicines for Europe, which took place today, November 22, gathered a wide range of experts in the healthcare community to raise awareness and foster debate on a common approach to present solutions for patient-centric innovation and better patient access to these medicines.

Health delivery models in Europe are being challenged by an aging, rising patient population and current healthcare economic constraints, threatening the sustainability of Europe’s healthcare systems. There is a need for a new value proposition for patients, healthcare professionals and healthcare systems, especially to address clinical (adherence, quality of life) and economic inefficiencies. According to IQVIA, patient non-adherence is undoubtedly the biggest source of these, representing 57% of all inefficiency costs, and limiting the ability for patients to best manage their condition. Value added medicines can address these challenges by improving patient adherence and quality-of-life issues, while addressing medicine-related healthcare inefficiencies and improving healthcare provision and organization thereby contributing to the sustainability of healthcare systems.

Marc-Alexander Mahl, Medicines for Europe president, highlighted that “we have a responsibility to look at European healthcare systems and see how we can contribute value to patients, healthcare professionals and society. Value added medicines deliver patient-centric gains. To continue the development of this sustainable innovation, there is a need for a favorable environment, where the development efforts can be reasonably recognized, and the access to value added medicines is well integrated in healthcare systems.’